This is a StreetInsider.com Premium Only Page

TherapeuticsMD (TXMD) – Business Wire

Mar 29, 2024 04:00 PM TherapeuticsMD Announces Full Year 2023 Financial Results

Nov 14, 2023 04:05 PM TherapeuticsMD Announces Third Quarter 2023 Financial Results

Aug 14, 2023 06:50 AM TherapeuticsMD Announces Second Quarter 2023 Financial Results

May 15, 2023 04:05 PM TherapeuticsMD Announces First Quarter 2023 Financial Results

Apr 7, 2023 04:01 PM TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Jan 3, 2023 06:50 AM TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Dec 4, 2022 06:00 PM TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Nov 14, 2022 04:05 PM TherapeuticsMD Announces Third Quarter 2022 Financial Results

Oct 31, 2022 06:50 AM TherapeuticsMD Announces Additional $7 Million Private Placement

Oct 3, 2022 06:50 AM TherapeuticsMD Announces $7 Million Private Placement

Sep 12, 2022 06:50 AM TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Aug 15, 2022 06:50 AM TherapeuticsMD Announces Second Quarter 2022 Financial Results

Aug 8, 2022 08:45 AM CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

Aug 8, 2022 06:50 AM TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 1, 2022 06:50 AM TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Jul 13, 2022 06:50 AM TherapeuticsMD Announces Expiration of Tender Offer

May 31, 2022 06:00 AM  TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 20, 2022 09:43 AM TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 16, 2022 04:05 PM TherapeuticsMD Announces First Quarter 2022 Financial Results

May 10, 2022 04:05 PM TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

Apr 14, 2022 04:15 PM TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Mar 10, 2022 06:50 AM TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Mar 7, 2022 07:40 AM TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

Mar 1, 2022 04:30 PM TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

Feb 18, 2022 02:00 AM Karen L. Ling joins Galderma’s Advisory Committee

Dec 10, 2021 04:30 PM U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

Dec 8, 2021 06:50 AM TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

Nov 11, 2021 06:50 AM  TherapeuticsMD Announces Third Quarter 2021 Financial Results

Nov 11, 2021 06:45 AM TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer

Oct 27, 2021 05:00 PM TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

Oct 15, 2021 05:33 PM TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Sep 21, 2021 07:45 AM Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Sep 2, 2021 06:50 AM Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month

Aug 23, 2021 06:50 AM TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Aug 9, 2021 04:30 PM TherapeuticsMD Announces Appointment of Hugh O’Dowd as President

Aug 4, 2021 06:50 AM TherapeuticsMD Announces Second Quarter 2021 Financial Results

Jul 26, 2021 06:50 AM TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

May 25, 2021 06:50 AM TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

May 24, 2021 07:00 AM The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

May 6, 2021 07:00 AM TherapeuticsMD Announces First Quarter 2021 Financial Results

May 3, 2021 07:00 AM TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting

Apr 29, 2021 07:00 AM TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021

Apr 8, 2021 04:05 PM TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium

Mar 3, 2021 04:28 AM EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement Therapy

Mar 2, 2021 07:00 AM TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results

Mar 1, 2021 07:00 AM TherapeuticsMD Announces Participation in Upcoming Investor Conferences

Feb 23, 2021 04:05 PM TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

Feb 16, 2021 04:01 PM TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock

Feb 11, 2021 09:02 AM TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock

Feb 10, 2021 04:01 PM TherapeuticsMD Announces Underwritten Public Offering of its Common Stock